Resverlogix Provides Research and Development Update in New York City

TSX Exchange Symbol: RVX

CALGARY and NEW YORK, Sept. 29, 2015 /CNW/ - Resverlogix Corp. (TSX: RVX) (the "Company") today announced that the Resverlogix clinical and science teams, along with two members of the international clinical steering committee for the upcoming BETonMACE study, presented a Research and Development Update for RVX-208 "apabetalone" on September 25, 2015 in New York City.

Highlights from the presentation included an in depth analysis of the large unmet medical need in diabetes patients at high risk for secondary major adverse cardiovascular events ("MACE") presented by the chair of the BETonMACE clinical steering committee, Professor Kausik K. Ray, BSc , MBChB, MD, MPhil, FACC, FAHA, FESC, FRCP. In addition, a breakdown of the unmet medical need in Chronic Kidney Disease and the therapeutic potential of apabetalone in this indication were presented by clinical steering committee member, Dr. Kamyar Kalantar-Zadeh, MD, MPH, PhD, FAAP, FACP, FASN, FAHA, FNKF.

Senior Vice President of Clinical Development, Dr. Mike Sweeney, MD detailed the final design of the BETonMACE clinical trial, and Vice President of Scientific Development, Dr. Ewelina Kulikowski, PhD highlighted novel biology and findings from ongoing mechanistic studies focused on cardiovascular risk pathways and apabetalone's potential in reducing MACE.  Kenneth Lebioda, Senior Vice President of Business and Corporate Development finished with a discussion of findings from primary market research focusing on primary care physician and payer perceptions of apabetalone.

The presentation is available via web replay. To access the presentation, please click here:

About Resverlogix

Resverlogix is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET bromodomain inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is the first and only BET inhibitor selective for the second bromodomain (BD2) within the BET protein called BRD4. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with diseases such as high-risk cardiovascular disease (CVD), diabetes mellitus (DM), Alzheimer's disease, peripheral artery disease, and chronic kidney disease while maintaining an excellent safety profile. Apabetalone is the only selective BET bromodomain inhibitor in human clinical trials. Resverlogix's Phase 3 clinical trial BETonMACE in high-risk CVD patients with DM and low HDL is planned to commence in the fall of 2015. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit We can be followed on our blog at and via Twitter @Resverlogix_RVX

Company Contacts:

Donald J. McCaffrey
President and CEO
Resverlogix Corp.
Phone: 403-254-9252

Kenneth Lebioda
SVP Business & Corporate Development
Resverlogix Corp.
Phone: 403-254-9252

Sarah Zapotichny
Director, Investor Relations & Corporate Communications
Resverlogix Corp. 
Phone: 403-254-9252 

SOURCE Resverlogix Corp.


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890